P2RY12 and myocardial infarction: GRAVITAS trial (Gauging Responsiveness with a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety) has setup the cut‐off value for clopidogrel high on‐treatment platelet reactivity (HTPR) as ≥208 P2Y12 PRU, which has been found in more than half of the selected subjects and has shown a >5‐fold increased risk of cardiovascular death, myocardial infarction, and stent thrombosis at 60 days.109